
Nikolaj KunÃ,e

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9350439/publications.pdf Version: 2024-02-01



Νικοιλι Κιινά ε

#	Article	IF	CITATIONS
1	Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence. JAMA Psychiatry, 2017, 74, 1197.	11.0	200
2	Drug Screening of Hair by Liquid Chromatography-Tandem Mass Spectrometry. Journal of Analytical Toxicology, 2008, 32, 364-372.	2.8	83
3	Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. British Journal of Psychiatry, 2009, 194, 541-546.	2.8	83
4	Naltrexone Implants Compared to Methadone: Outcomes Six Months after Prison Release. European Addiction Research, 2010, 16, 139-145.	2.4	74
5	Sustained-Release Naltrexone For Opioid Dependence. The Cochrane Library, 2008, , CD006140.	2.8	67
6	Naltrexone Depot Formulations for Opioid and Alcohol Dependence: A Systematic Review. CNS Neuroscience and Therapeutics, 2011, 17, 629-636.	3.9	57
7	Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. British Journal of Clinical Pharmacology, 2014, 77, 264-271.	2.4	51
8	Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone. JAMA Psychiatry, 2019, 76, 127.	11.0	44
9	Challenges to antagonist blockade during sustainedâ€release naltrexone treatment. Addiction, 2010, 105, 1633-1639.	3.3	21
10	Retention in naltrexone implant treatment for opioid dependence. Drug and Alcohol Dependence, 2010, 111, 166-169.	3.2	21
11	Treatment research in prison: Problems and solutions in a randomized trial. Addiction Research and Theory, 2010, 18, 1-13.	1.9	20
12	Effectiveness, safety and feasibility of extendedâ€release naltrexone for opioid dependence: a 9â€month followâ€up to a 3â€month randomized trial. Addiction, 2018, 113, 1840-1849.	3.3	20
13	Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). BMC Pharmacology & Toxicology, 2016, 17, 18.	2.4	18
14	No increased pain among opioidâ€dependent individuals treated with extendedâ€release naltrexone or buprenorphineâ€naloxone: A 3â€month randomized study and 9â€month openâ€treatment followâ€up study. American Journal on Addictions, 2019, 28, 77-85.	1.4	16
15	The Norwegian Offender Mental Health and Addiction Study – Design and Implementation of a National Survey and Prospective Cohort Study. Substance Abuse: Research and Treatment, 2015, 9s2, SART.S23546.	0.9	12
16	Intact responses to non-drug rewards in long-term opioid maintenance treatment. Neuropsychopharmacology, 2019, 44, 1456-1463.	5.4	10
17	Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. European Addiction Research, 2019, 25, 303-309.	2.4	7
18	Interest in Extended Release Naltrexone among Opioid Users. European Addiction Research, 2016, 22, 301-305.	2.4	5

Nikolaj KunÃ,e

#	Article	IF	CITATIONS
19	Adapting treatment length to opioidâ€dependent individuals' needs and preferences: a 2â€year followâ€up to a 1â€year study of extendedâ€release naltrexone. Addiction, 2021, 116, 2084.) 3.3	5
20	Opioid overdose deaths can occur in patients with naltrexone implants. Medical Journal of Australia, 2007, 187, 56-56.	1.7	3
21	The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse. European Addiction Research, 2022, 28, 56-67.	2.4	3
22	Risk of Relapse Among Opioidâ€Đependent Patients Treated With Extendedâ€Release Naltrexone or Buprenorphineâ€Naloxone: A Randomized Clinical Trial. American Journal on Addictions, 2021, 30, 453-460.	1.4	2
23	BLAME THE COUNSELLING, NOT THE IMPLANT. A RESPONSE TO OLIVER, HORSPOOL & KEEN (2005). Addiction, 2005, 100, 1027-1028.	3.3	1
24	T212. No Increase in Chronic Pain Among Opioid-Dependent Individuals Randomized to Treatment With Extended-Release Naltrexone Compared to Buprenorphine-Naloxone. Biological Psychiatry, 2019, 85, S211-S212.	1.3	1
25	Commentary on Nunes et al . (2020): Blocked opioid use in antagonist treatment—time for cognitive and userâ€centered perspectives. Addiction, 2020, 115, 247-248.	3.3	1
26	Treatment research in prison: Problems and solutions in a randomized trial. Addiction Research and Theory, 0, , 1-13.	1.9	1
27	Protocol for the Lovisenberg Open Acute Door Study (LOADS): a pragmatic randomised controlled trial to compare safety and coercion between open-door policy and usual-care services in acute psychiatric inpatients. BMJ Open, 2022, 12, e058501.	1.9	1
28	Patients receiving opiate substitution have elevated mortality risks at the start and end of treatment. Evidence-Based Mental Health, 2011, 14, 39-39.	4.5	0
29	Extended-release opioid antagonists and HIV treatment. Lancet HIV,the, 2019, 6, e206-e207.	4.7	0
30	Opioid addiction: long-acting formulations for a long-term disorder. Lancet, The, 2019, 393, 723-724.	13.7	0
31	Sustained release Naltrexone, a promising alternative in treatment of opiate addiction. Canadian Journal of Addiction, 2009, 1, 42.	0.4	0
32	Patients receiving opiate substitution have elevated mortality risks at the start and end of treatment. Evidence-Based Mental Health, 2011, 14, 39-39.	4.5	0